Crown Bioscience, Inc. Strengthens Pre-Clinical Leadership Team With Senior Appointment

Santa Clara, CA (28th January 2015) – Crown Bioscience, Inc., a leading global drug discovery and development service company has announced the appointment of Laurie Heilmann as the new Senior Vice President Global Strategy, Marketing Business Development. The new appointment coincides with a substantial increase in business growth and recent expansion and will act to further strengthen Crown's global presence.

Bringing over 30 years' experience in medical and life science services, Heilmann has extensive experience and a proven track record for building world class teams and consistently increasing sales results, profits, market share and new market development. Her multifaceted experience in medical devices, software, Phase I-IV clinical research and knowledge of FDA and sponsor requirements in the US, Europe, India and Asia will prove to be an important asset in Crown's strategic expansion into the clinical services market.

Prior to joining Crown Bioscience, Heilmann has held several senior positions in prominent drug and device development companies, including American College of Radiology for profit imaging CRO, Image Metrix, Co-founder and Senior Vice President of Ockham Development Group. Heilmann has also been honored multiple times as part of the President's Club and as the National Account Manager of the year for Spacelabs Medical and is an active member of DIA.

"We are delighted to welcome Laurie to our team" comments Jean Pierre Wery, President of Crown Bioscience. "We have an ambitious growth strategy for our Translational Service Platforms and Laurie's hands-on experience with strategic vision in marketing and business development will be instrumental in the effort to drive forward our global operations. Her invaluable perspectives will considerably increase our influence in the global pre-clinical arena, allowing Crown to pursue helping our clients improve clinical outcomes for patients throughout the world."

This recruitment drive follows recent announcements by Crown Bioscience Inc., including the opening of a new facility in Kannapolis in October 2014, as well as an expansion of the Crown Bioscience UK facility based in Nottingham in January 2015. This activity signals the next stage in Crown's global strategy to increase access to its service platforms, step up European operations and increase the company's visibility as a global provider of preclinical CRO services.

For further information about Crown Bioscience visit the website at:

~ ENDS ~

For further press information please contact: James Hayward - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: [email protected]

About Crown Bioscience Inc.

Founded in 2006, Crown Bioscience is a premier drug discovery and development service company providing cutting-edge translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas: Oncology and Metabolic Disease. Our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™ and HuSignature™ platforms enable unique lead optimization and translational strategies to deliver superior clinical candidates. Headquartered in Santa Clara California, Crown Bioscience has operations in China (Beijing and Jiangsu Taicang), United Kingdom (Crown Bioscience UK Ltd. In Nottingham) and the USA (NC) with business offices in Boston, Princeton, RTP, Phoenix, Milan and Shanghai. For more information, please visit

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.

The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.